Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
The follicular lymphoma clinical trial analysis report delivers important insights into ongoing research of 50+ pipeline follicular lymphoma drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
New York, USA, April 21, 2026 (GLOBE NEWSWIRE) — Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
The follicular lymphoma clinical trial analysis report delivers important insights into ongoing research of 50+ pipeline follicular lymphoma drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
DelveInsight’s ‘Follicular Lymphoma Pipeline Insight 2026’ report provides comprehensive global coverage of pipeline therapies for follicular lymphoma across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the follicular lymphoma domain.
Follicular Lymphoma Clinical Trial Analysis Summary
- DelveInsight’s follicular lymphoma pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline follicular lymphoma drugs.
- Key follicular lymphoma companies, such as AstraZeneca, Bristol-Myers Squibb, Xynomic Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme, Nurix Therapeutics, Inc., Carna Biosciences, Inc., and others, are evaluating new follicular lymphoma drugs to improve the treatment landscape.
- Promising pipeline follicular lymphoma therapies, such as AZD0486, Golcadomide, Abexinostat, SHR 2554, Zilovertamab vedotin, NX-2127, AS-1763, and others, are in different phases of follicular lymphoma clinical trials.
- Approximately 5+ follicular lymphoma drugs are in the late stages of development.
- Notable MoAs in follicular lymphoma clinical trials include Antibody-dependent cell cytotoxicity, CRBN protein modulator, Histone deacetylase inhibitors, Enhancer of zeste homolog 2 protein inhibitor, Receptor tyrosine kinase-like orphan receptor 1 inhibitor, IKZF1 protein degraders, IKZF3 protein degraders, Agammaglobulinaemia tyrosine kinase inhibitors, and others.
Request a sample and discover the recent advances in follicular lymphoma drug development @ https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight
What is Follicular Lymphoma
Follicular lymphoma is a slow-growing type of Non-Hodgkin lymphoma that arises from B lymphocytes, a kind of white blood cell responsible for producing antibodies. It typically originates in lymph nodes but can also involve the bone marrow and other organs. The disease is characterized by abnormal, uncontrolled growth of follicle center B cells, often linked to a genetic alteration involving the BCL2 gene, which prevents normal cell death. Patients may experience painless swelling of lymph nodes, fatigue, or no symptoms at all in the early stages, leading to delayed diagnosis. While generally considered indolent, follicular lymphoma is usually not curable with standard therapies, though many patients live for years with treatment approaches such as immunotherapy, targeted therapy, and chemotherapy.
Find out more about follicular lymphoma drugs @ Follicular Lymphoma Treatment
A snapshot of the Pipeline Follicular Lymphoma Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| AZD0486 | AstraZeneca | III | Antibody-dependent cell cytotoxicity | IV |
| Golcadomide | Bristol-Myers Squibb | III | CRBN protein modulator | Oral |
| Abexinostat | Xynomic Pharmaceuticals | II | Histone deacetylase inhibitors | Oral |
| SHR-2554 | Jiangsu HengRui Medicine / Treeline Biosciences | II | Enhancer of zeste homolog 2 protein inhibitor | Oral |
| Zilovertamab vedotin | Merck Sharp & Dohme | II | Receptor tyrosine kinase-like orphan receptor 1 inhibitor | IV infusion |
| NX-2127 | Nurix Therapeutics, Inc. | I | BTK inhibitor; IKZF1 protein degraders; IKZF3 protein degraders | Oral |
| AS-1763 | Carna Biosciences, Inc. | I | Agammaglobulinaemia tyrosine kinase inhibitors | Oral |
Learn more about the emerging follicular lymphoma therapies @ Follicular Lymphoma Clinical Trials
Stuti Mahajan, consulting manager at DelveInsight, said that the emerging therapeutic landscape for follicular lymphoma demonstrates a diverse and mechanism-driven pipeline, with multiple mid- to early-stage candidates advancing beyond conventional anti-CD20 approaches. Late-stage development highlights continued innovation in immune-mediated cytotoxicity and cereblon (CRBN) modulation, reflecting a shift toward enhanced immune engagement and targeted protein degradation. Phase II therapies emphasize precision oncology through epigenetic modulation, EZH2 inhibition, and antibody-drug conjugates, indicating a strong focus on improving efficacy while minimizing systemic toxicity. Early-stage candidates further reinforce this trend with targeted protein degraders and kinase inhibitors, particularly in BTK and related pathways. Overall, the pipeline reflects robust innovation with a clear shift toward targeted, oral, and patient-centric therapies, which are expected to enable more personalized treatment approaches and improve long-term disease management outcomes in follicular lymphoma.
Recent Developments in Follicular Lymphoma Treatment Space
- In February 2026, Lyell Immunopharma, Inc. announced that the first patient has been dosed in the PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line (2L) setting.
- In January 2026, the European Medicine Agency (EMA) granted Orphan Drug Designation to surovatamig for the treatment of follicular lymphoma.
- In October 2025, Verismo Therapeutics announced that it had treated the first patient with follicular lymphoma (FL) in its CELESTIAL-301 Phase I clinical trial of SynKIR™-310.
- In October 2025, Enterome announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for follicular lymphoma in the low tumor burden “watch-and-wait” setting for its lead OncoMimics™ immunotherapy, EO2463. The decision highlights EO2463’s efficacy, excellent safety and tolerability as a first-in-class monotherapy in clinical testing to date in patients who currently do not normally receive any treatment as long as they do not show clinical symptoms, despite having been diagnosed with a cancer that progresses in the vast majority of cases.
- In May 2025, PeproMene Bio, Inc. announced that the first r/r FL patient treated in its phase I PMB-102 study, r/r B-cell non-Hodgkin’s Lymphoma (r/r B-NHL) trial of PMB-CT01 (BAFFR-CAR T Cells), has achieved complete remission at one month post treatment.
Scope of the Follicular Lymphoma Pipeline Report
- Coverage: Global
- Follicular Lymphoma Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Follicular Lymphoma Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Follicular Lymphoma Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
- Follicular Lymphoma Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
- Follicular Lymphoma Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, CRBN protein modulator, Histone deacetylase inhibitors, Enhancer of zeste homolog 2 protein inhibitor, Receptor tyrosine kinase-like orphan receptor 1 inhibitor, IKZF1 protein degraders, IKZF3 protein degraders, Agammaglobulinaemia tyrosine kinase inhibitors, and others
- Key Follicular Lymphoma Companies: AstraZeneca, Bristol-Myers Squibb, Xynomic Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme, Nurix Therapeutics, Inc., Carna Biosciences, Inc., and others.
- Key Follicular Lymphoma Pipeline Therapies: AZD0486, Golcadomide, Abexinostat, SHR 2554, Zilovertamab vedotin, NX-2127, AS-1763, and others.
Dive deep into rich insights for new follicular lymphoma treatments, visit @ Follicular Lymphoma Drugs
Table of Contents
| 1. | Follicular Lymphoma Pipeline Report Introduction |
| 2. | Follicular Lymphoma Pipeline Report Executive Summary |
| 3. | Follicular Lymphoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Follicular Lymphoma Clinical Trial Therapeutics |
| 6. | Follicular Lymphoma Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Follicular Lymphoma Pipeline: Late-Stage Products (Phase III) |
| 8. | Follicular Lymphoma Pipeline: Mid-Stage Products (Phase II) |
| 9. | Follicular Lymphoma Pipeline: Early-Stage Products (Phase I) |
| 10. | Follicular Lymphoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Follicular Lymphoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Follicular Lymphoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the follicular lymphoma cure research, reach out @ Medication for Follicular Lymphoma Treatment
Related Reports
Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key follicular lymphoma Market companies, including Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, and others.
Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-Hodgkin’s lymphoma companies, including Soligenix, Innate Pharma, Nurix Therapeutics, AstraZeneca, Merck, Prescient Therapeutics, Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member of Roche), Bristol Myers Squibb, and others.
Non-Hodgkin’s Lymphoma Clinical Trial Analysis
Non-Hodgkin’s Lymphoma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Bristol-Myers Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA, and others.
Cutaneous T-cell Lymphoma Market
Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, and others.
Diffuse Large B-cell Lymphoma Market
Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. TheNewsHeadliner.com takes no editorial responsibility for the same.